https://klse.i3investor.com/blogs/changwt/2020-11-
Post# of 36537
(Total Views: 490)
Posted On: 11/16/2020 3:35:21 AM
https://klse.i3investor.com/blogs/changwt/202...accine.jsp
“The results of the ex-vivo human blood screen to date are very encouraging, with demonstrated T helper cell activation, no Th2 response, and positive antibody binding in serum. Through targeted immune system regulation, we are developing the Ii-Key COVID vaccine as a "Complete Vaccine" that activates both the cellular and humoral (antibody) responses to provide long-term immune memory for protection from SARS-CoV-2 infection and COVID-19.”
“The results of the ex-vivo human blood screen to date are very encouraging, with demonstrated T helper cell activation, no Th2 response, and positive antibody binding in serum. Through targeted immune system regulation, we are developing the Ii-Key COVID vaccine as a "Complete Vaccine" that activates both the cellular and humoral (antibody) responses to provide long-term immune memory for protection from SARS-CoV-2 infection and COVID-19.”
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼